Press Release Archive

04.20.2017

Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders

04.20.2017

PSI And Pfizer Partner To Address Hypertension In Vietnam And Myanmar

03.31.2017

IBRANCE® (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer

03.27.2017

XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)

03.24.2017

Pfizer Receives Positive CHMP Opinion for TRUMENBA® for Prevention of Meningococcal Group B Disease

03.23.2017

FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma

03.21.2017

NephCure Kidney International® Launches the NephCure Accelerating Cures Institute® Aims to accelerate treatments and a cure for glomerular kidney diseases

03.21.2017

New drug strategy: target the ribosome to halt protein production

03.17.2017

DILIsym Services, Inc. Evaluates Prospective NAFLD Treatment, Utilizing Its Flagship Technology in Collaboration with Pfizer, Inc.

03.17.2017

Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation

03.15.2017

Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis

03.08.2017

Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia